RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve disease-free survival (DFS) compared to SOC observation in patients with resected PDAC who have completed neoadjuvant and/or adjuvant chemotherapy.
Inclusion Criteria:
Exclusion Criteria:
medinfo@revmed.com1-844-2-REVMED
Phoenix, Arizona 85054, United States
bekaii-saab.tanios@mayo.edu480-342-4800
Los Angeles, California 90048, United States
Miami, Florida 33136, United States
Lawrence, Kansas 66045, United States
Baltimore, Maryland 21287, United States
New York, New York 10016, United States
Milwaukee, Wisconsin 53226, United States
Birmingham, B15 2TH, United Kingdom
London, SW3 6JJ, United Kingdom
London, W12 0HS, United Kingdom
sdad@health.ucsd.edu858-822-5376
naomi.geier@cshs.org310-423-4693
mmanahan@mednet.ucla.edu310-633-8400 ext. x19212
cblake1@stanford.edu650-725-9895
Kevin.lopez@ucsf.edu415-502-3310
jennifer.hege@usoncology.com303-388-4876
jonathan.steinmetz@hhchealth.org860-972-4183
babiker.hani@mayo.edu520-626-7866
yxj512@med.miami.edu305-243-2647
727-216-1143
kathleen.marie.coleman@emory.edu404-251-1278
anorris@ecommunity.com317-621-3858
giclinicaltrials@jhmi.edu410-614-3644
202-660-6500
617-632-3000
carr.ryan@mayo.edu507-284-2511
mroth@saint-lukes.org816-932-2677
ann.lovelace@usoncology.com702-609-9460
Ct.gov@nyulangone.org212-731-6120
Ct.gov@nyulangone.org212-731-6120
cancerclinicaltrials@cumc.columbia.edu
oreillye@MSKCC.ORG646-888-4182
WCICTOResearch@URMC.Rochester.edu585-275-4401
sambrose@tcrcpt.org567-402-4502
heidi.mckean@avera.org605-322-6900
GIClinicalTrials@mdanderson.org713-794-1623
Angie.smith2@usoncology.com
susan.sharry@hci.utah.edu801-585-3453
dcarini@mcw.edu414-805-0789
christoph.springfeld@med.uni-heidelberg.de+49 6221 56 6857
kccmakoto23u@gmail.com
masikeda@east.ncc.go.jp81471331111
cmorizan@ncc.go.jp
masato.ozaka@jfcr.or.jp
info@panoncologytrials.com787-407-3333
dongahicrc33@naver.com82512402576
ohdoyoun@snu.ac.kr82220720701
yooc@amc.seoul.kr82230101727
oncopark@skku.edu821099333457
esgonzalez@unav.es0034 948255400 ext. 2712
jperera@vhio.net0034 932543454 ext. 1256
macarulla@clinic.cat0034 932275402
0034 913908003
inmaculada.gallego.jimenez.sspa@juntadeandalucia.es0034 955018613
lsaz@incliva.es0034 629260816
Shivan.Sivakumar@uhb.nhs.uk0121 371 3571
gitrials@rmh.nhs.uk02078118460
michela.cicchetti@nhs.ne0203 313 8364